Page 6 - Mark Neumann News Today

Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) had its price target raised by Mizuho from $66.00 to $74.00 in a research note released on Wednesday, The Fly reports. They currently have a buy rating on the biopharmaceutical company’s stock. ITCI has been the topic of a number of other research reports. Needham & Company LLC restated […]

Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) had its target price increased by Canaccord Genuity Group from $93.00 to $98.00 in a report published on Wednesday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts have also weighed in on ITCI. Needham & Company […]

Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) had its price target upped by Bank of America from $62.00 to $63.00 in a research report released on Wednesday, The Fly reports. They currently have a buy rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald restated an overweight […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) EVP Mark Neumann sold 15,604 shares of Intra-Cellular Therapies stock in a transaction on Tuesday, March 28th. The stock was sold at an average price of $54.31, for a total value of $847,453.24. Following the sale, the executive vice president now directly owns 45,339 shares of the company’s […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) was down 2.7% on Friday after an insider sold shares in the company. The company traded as low as $54.26 and last traded at $54.56. Approximately 279,286 shares traded hands during mid-day trading, a decline of 63% from the average daily volume of 754,600 shares. The stock had […]

The Associated recently launched their original streaming service, offering Jewish video programming to entertain and educate.

Ensign Peak Advisors Inc reduced its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 80.6% in the third quarter, Holdings Channel reports. The fund owned 24,340 shares of the biopharmaceutical company’s stock after selling 101,153 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Intra-Cellular Therapies were worth $1,133,000 at […]

Operator: Thank you for standing by and welcome to the Intra-Cellular Therapies Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

The owner hopes tourist traffic from Watkins Glen State Park and Watkins Glen International will make Upstate Brewing Company a beer destination.

The owner hopes tourist traffic from Watkins Glen State Park and Watkins Glen International will make Upstate Brewing Company a beer destination.